Special Issue

Head and Neck Cancer— Diagnostics, Prevention and Management

Message from the Guest Editor

Head and neck cancer is the seventh most common type of cancer worldwide and comprises a diverse group of tumors affecting the upper aerodigestive tract. In 2018, 890,000 new cases and 450,000 deaths were reported globally.

We are pleased to invite you to submit basic research aimed at improving technologies for the prevention, diagnosis, risk assessment, and treatment of head and neck cancer.

This Special Issue aims to familiarize physicians and researchers with the latest advances in such research from the standpoint of diagnostics, prevention, and management. We welcome original research articles and reviews, with research areas including (but not limited to):

Experimental research in the field of head and neck cancer; Genomics, GWAS, and population genetics in head and neck cancer; Head and neck cancer epigenetics; Proteomic investigation of head and neck cancer; Etiopathogenetic aspects of head and neck cancer; Metabolic disorders of head and neck cancer; Tumor microenvironment of head and neck cancer; Individual management of head and neck cancer; Lineage tracing and evolution of head and neck cancer.

Guest Editor

Prof. Dr. Demeng Chen

Center for Translational Medicine, The First Affiliated Hospital, Sun Yatsen University, Guangzhou 510080, China

Deadline for manuscript submissions

closed (20 June 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/153601

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

